Shots:

• Chugai get an exclusive development and commercialization agreement in Japan for Roche’s Ab cocktail of casirivimab and imdevimab to combat COVID-19
• Earlier- Roche & Regeneron collaborated for the development & commercialization of Ab cocktail where Regeneron will distribute the treatment in the US while Roche will be lead manufacturing and distribution activities outside the US
• The combination regimen is being studied globally in a P-II/III study for patients with COVID-19 who require hospitalization- in P-II/III clinical study for non-hospitalized patients with COVID-19- and P-III clinical study for prevention of infection in COVID-19 household contacts

 ­ Ref: Chugai | Image: Roche